COMMITTED TO DISCOVERING BEST-IN-CLASS ORAL THERAPIES
TO CONQUER CANCER AND INFLAMMATORY DISEASE

RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing our proprietary drug discovery and development engine, we develop highly selective small molecules that are designed to modulate the critical immune responses underlying these diseases. Since our founding, we have discovered and advanced unique two drug candidates each targeting CCR4. Our lead oncology drug candidate, FLX475, reached the clinic in just two and a half years, and our lead inflammation drug candidate, RPT193, entered the clinic in August 2019. We are also pursuing a range of targets, including GCN2 and HPK1, that are in earlier stages of discovery and development. We believe our unwavering focus, applying scientific rigor and discipline to advance oral treatments that intelligently target key drivers of the immune system, could result in drug candidates that, if approved, will combat cancer and allergic diseases and, importantly, improve patients’ lives.